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Abstract
Background: Bipolar disorder is a common long-term mental health condition characterised by episodes of mania
or hypomania and depression resulting in disability, early death, and high health and society costs. Public money
funds the National Institute of Healthcare and Clinical Excellence (NICE) to produce clinical guidelines by systematically
identifying the most up to date research evidence and costing its main recommendations for healthcare organisations
and professionals to follow in England and Wales. Most governments, including those of England and Wales, need to
improve healthcare but at reduced cost. There is evidence, particularly in bipolar disorder, that systematically following
clinical guidelines achieves these outcomes.
Discussion: NICE clinical guidelines, including those regarding bipolar disorder, remain variably implemented. They give
clinicians and patients a non-prescriptive basis for deciding their care. Despite the passing of the Health and Social Care
Act in 2012 in England requiring all healthcare organisations to consider NICE clinical guidelines in commissioning,
delivering, and inspecting healthcare services, healthcare organisations in the National Health Service may ignore them
with little accountability and few consequences. There is no mechanism to ensure that healthcare professionals know or
consider them. Barriers to their implementation include the lack of political and professional leadership, the complexity
of the organisation of care and policy, mistrust of some processes and recommendations of clinical guidelines, and a lack
of a clear implementation model, strategy, responsibility, or accountability. Mitigation to these barriers is presented herein.
Summary: The variability, safety, and quality of healthcare might be improved and its cost reduced if the implementation
of NICE clinical guidelines, such as those for bipolar disorder, were made the minimum starting point for clinical decision-
making and mandatory responsibilities of all healthcare organisations and professionals.
Keywords: Bipolar disorder, Clinical guideline, Compulsion, Implementation, National Institute of Healthcare and Clinical
Excellence (NICE), Organisation of care, Policy, Professional responsibility
Background
Bipolar disorder is a serious mental illness and a long-
term condition characterised by recurrent episodes of
mania or hypomania (elated mood, overactivity, disin-
hibition, and inflated self-esteem lasting at least 4 days)
and depression lasting for 2 weeks interspersed by pe-
riods of being well or less severe symptoms [1]. World-
wide, among all health conditions, it is the 18th leading
cause of years lost due to disability [2], with a peak age of
onset between 13 and 30 years of age [3]. Standardised
mortality ratios for all causes, cardiovascular disease and
respiratory disease and suicide are all increased when
coupled to the condition [4]. Acute mania is treated with
antipsychotic drugs that differ in their clinical effect-
iveness and acceptability [5]. Acute bipolar depression
is usually treated with a range of medication, while
lithium remains one of the main approaches to long-
term management [6]. There is accumulating evidence
for the effectiveness of psychological treatments for
bipolar depression and long-term management [7].
Some of the changes to practice proposed in the
National Institute of Healthcare and Clinical Excel-
lence (NICE) Clinical Guideline for Bipolar Disorder
in 2014 [8] challenge long-standing clinical practice,
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e.g. antidepressants other than fluoxetine with olanzapine
are not recommended to treat acute bipolar depression.
The new clinical guideline explicitly promotes collabora-
tive clinical practice with patients and carers based on
recovery goals.
NICE was formed in 1999 by the United Kingdom
government to develop national standards of healthcare
to reduce variation in clinical care across different parts
of England and Wales, but not Scotland and Northern
Ireland, where the devolved government sets health
policy. NICE now produces different types of guidance:
clinical guidelines for healthcare, public health guide-
lines, social care guidelines, technology appraisal, and
guidance on interventional procedures, medical technolo-
gies, and diagnostic agents [9]. Only some technology ap-
praisals are mandatory for implementation by publicly
funded healthcare organisations, namely the National
Health Service (NHS) in England and Wales. Clinical
guidelines consider the whole care pathway for a condi-
tion from primary care to secondary care. NICE Quality
Standards [10] (Box 1) are specific measurable statements
derived principally from the NICE clinical guidelines when
practice is variable, but the evidence base for recommen-
dations from the guideline is robust. They are auditable
for quality improvement so that commissioners and ser-
vices can demonstrate whether practice has improved.
Neither clinical guidelines nor quality standards are
mandatory for implementation by healthcare organisa-
tions or health professionals. It is the author’s view that
they should be the starting point for all clinical care and,
with respect to all recommendations concerning safety,
the minimum standard of care expected in the NHS. Their
implementation should be a mandatory responsibility
for all healthcare commissioners, providers, inspection
bodies, health professionals, and professional bodies
responsible for licensing, registration, training, and re-
validation. Otherwise, access to high standards of prac-
tice will remain variable, patients and carers are not
empowered because they do not know what to expect,
and care is less clinically safe, effective, and cost-effective
than it should be.
The case for the mandatory implementation of NICE
guidelines
Box 2 summarises the potential benefits of the mandatory
implementation of NICE clinical guidelines. Legislation
was passed to promote the consideration of NICE clinical
guidelines for health conditions by all NHS organisations
in England under the Health and Social Care Act (2012)
[11], and set up a number of other bodies such as
Academic Health Science Networks and strategic clinical
networks to help implement evidence-based care and
innovation, including NICE clinical guidelines, into prac-
tice (Fig. 1). NICE clinical guidelines are best considered
as a starting point for clinical care and are not designed to
cover every clinical situation that may arise, so health pro-
fessionals and NHS organisations must use their judge-
ment to optimise clinical care for each patient they see
[12]; these may be useful in other countries who wish to
adopt the approach [13, 14]. Like most NICE clinical
guidelines, the 2006 NICE Clinical Guideline for Bipolar
Disorder [15] seems to have been incompletely and
variably implemented [16]. For instance, the 2006 NICE
Clinical Guideline for Bipolar Disorder recommenda-
tions concerning lithium monitoring were followed in
48–70 % patients in a recent national audit [17], while
counselling about teratogenic risk and contraception in
women of childbearing age taking anticonvulsants was
only 22 % [18]. There is great variation in the imple-
mentation of NICE guidelines not only between organi-
sations but also within the same organisation over time
[19, 20]. In particular, NICE recommendations that re-
quire changes in the organisation of care or are con-
flicting to established practice are poorly implemented
[16]. A more standardised and systematic approach to
Box 1. Quality Standards for Bipolar Disorder 2015
1. Adults presenting in primary care with depression are offered
a referral for a specialist mental health assessment if they have
experienced overactivity or disinhibited behaviour lasting
4 days or more.
2. Adults with bipolar disorder have their early warning
symptoms and triggers of relapse, preferred response
during relapse, and personal recovery goals identified in
their care plan.
3. Adults with bipolar disorder are offered psychological
interventions specific for their disorder (developmental
standard).
4. Adults with bipolar disorder prescribed lithium have their
plasma lithium levels maintained at 0.6–0.8 mmol per litre.
5. Women (of childbearing potential) are not offered valproate
to treat bipolar disorder unless other treatments are
ineffective or not tolerated.
6. Adults with bipolar disorder have a physical health
assessment at least annually.
7. Adults with bipolar disorder who currently work, and those
who wish to find or return to work, receive supported
employment programmes.
8. Carers of adults with bipolar disorder are involved in care
planning, decision-making, and information sharing about
the person as agreed within the care plan.
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care as outlined by the NICE clinical guideline that is
still patient centred should reduce one source of vari-
ability of outcome in patients with bipolar disorder, a
condition with a highly variable outcome due to its nat-
ural history.
The same variable implementation of the NICE Clinical
Guideline for Bipolar Disorder may be repeated with the
2014 update, despite the Health and Social Care Act (2012),
because although NICE clinical guidelines must “be
carefully considered when developing strategies, planning
services and prioritising resources”, “commissioners reserve
the right not to implement NICE clinical guidelines” [21], as
do any other healthcare organisations or healthcare profes-
sionals, whether they are junior staff taking professional
examinations or senior health professionals who are consul-
tants in the topic of the clinical guideline facing appraisal
and revalidation. It is unclear who makes these decisions in
each healthcare body and there seem to be no lines of
accountability or transparency in their decision-making.
NICE clinical guidelines are often not considered in local
commissioning of healthcare unless public health clinicians
and more senior commissioners or national organisations
are involved [22, 23]. A striking example of the conse-
quences relates to the implementation of national guid-
ance on self-harm and suicide, which includes NICE
guidelines on self-harm, depression, and dual diagnosis
(serious mental illness including bipolar disorder and
alcohol or drug misuse) [24–26], as well as other pol-
icies [27]. Suicide rates fell between 1997 and 2006 in
those localities where key national recommendations
(24-hour crisis resolution and home treatment teams,
dual diagnosis teams, and multidisciplinary review of
suicide and other serious incidents) have taken place
compared to no change or rises in suicide rates in those
localities where these key recommendations were not
implemented [28].
Failure of a NHS organisation to implement NICE
clinical guidelines ought to be a rare decision that
should be publicly justified given that NICE clinical
guidelines are carefully costed and evidence based at a
time when the NHS has been handed the task of im-
proving quality of care whilst at the same time saving
£30 billion by 2020 [29]. NICE clinical guidelines are
developed after a thorough systematic review and
meta-analysis of the evidence from research, economic
modelling of key recommendations in the NICE guide-
line, and extensive iterative consultation with service
users, carers, a multidisciplinary group of primary and
secondary care clinicians, iteration with national and
international academic experts, and iteration with na-
tional organisations [30]. Similar input goes into the
development of care pathways, information for the
public, and quality standards to provide a suite of
tools that mental health services might utilise to help
implement NICE guidance through audit and quality
improvement.
Knowledge and practice in line with NICE clinical
guidelines is usually required for good or outstanding
ratings of the effectiveness of care when providers of
health services are inspected by the Care Quality Com-
mission [31]. Surprisingly, satisfactory care delivered by
healthcare organisations in England does not necessarily
require the demonstration of knowledge and practice in
Box 2. Potential benefits of mandatory implementation
of NICE Clinical Guidelines in bipolar disorder
1. Establish benchmarks and standards of care for professionals
and NHS-funded healthcare.
2. Improve outcomes by promoting interventions of benefit and
discourage ineffective interventions.
3. Reduce variation in care and one source of variability in
outcome in bipolar disorder which already has a variable
course due to its natural history.
4. Encourage collaborative care and continuity of care across
NHS organisations through greater clarity about care
pathway.
5. Reduced cost of care through greater consistency, increased
efficiency, and fewer avoidable adverse incidents.
6. Inform patients, carers, and the public about health
conditions and care to inform their decision-making when
self-managing, or seeking or discussing care with health
professionals.
7. Encourage health professionals to offer personalised care
based on recovery principles, i.e. based on what the
patient values.
8. Inform public policy.
9. Support quality improvement activities.
10. Improve quality of training of workforce in both how and
what care is delivered.
11. Focus by NHS and professional organisations on
implementing evidence-based care in local and personalised
contexts.
12. Improve quality of NICE clinical guidelines through greater
stakeholder engagement in the development of the guideline.
13. Greater expression of uncertainty in guideline and improved
targeting of applied research to address uncertainty.
14. Greater clarity for industry on how technology may improve
clinical care within the NHS by increasing consistency of care,
and clarifying areas of uncertainty in delivering care.
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line with NICE clinical guidelines even though they
cover patient safety, equity of access to care, and clinical
and cost effectiveness. There have been major failings in
the delivery of care to NHS organisations as outlined in
the Francis report [32] and other subsequent reports;
while the mandatory implementation of NICE clinical
guidelines was not a specific recommendation of the
Francis report, more robust support of its guidance and
specifically its quality standards was endorsed by NICE,
NHS England, and the Care Quality Commission (recom-
mendation 11), but undermined by national commission-
ing policy in the same year [21].
When implemented systematically in a care pathway,
NICE clinical guidelines may reduce the cost of care
without worsening clinical outcomes [33]; however, there
is a surprising lack of conclusive evidence on this issue.
Fig. 1 Relationships of NICE to National Health Services and Workforce organisations under Health and Social Act (2012). Indirect
relationships Direct relationships. Does not fully represent all social care, public health, third sector, and independent contractors.
England only. Wales is not represented
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Importantly, a recent randomised controlled trial showed
that guideline care involving a specialist bipolar disorder
pathway using British Association of Psychopharmacology
and NICE recommended treatments showed improved
clinical outcomes at two thirds the cost compared to usual
care by a community mental health team over 6 years
[34]. Better care for no extra costs has been achieved be-
fore for bipolar disorder and schizophrenia when clinical
guidelines have been followed [35]. There is also some evi-
dence that better evidence-based quality of care is not
only cost effective but cheaper [36, 37] because mistakes
and poor outcomes require additional care.
The case against mandatory implementation of NICE
clinical guidelines
Box 3 summarises the potential harms resulting from
the mandatory implementation of NICE clinical guide-
lines. A key issue is that the guideline accurately reflects
the balance of evidence and in particular is cautious
about recommendations that are very directive (i.e.
“offer” or “do not do” should be used only in the face of
compelling evidence versus “consider”), otherwise care
may be misguided, wasteful, or harmful [38]. Clinical
guidelines for bipolar disorder and other conditions vary
considerably in what they recommend, although such
variation may not matter provided the guideline is used
only as a starting point for clinical decision-making ra-
ther than constraint of patient-centred care [39, 40].
Despite efforts to achieve objectivity, consensus among
clinicians, patients, and carers, and transparency of
decision-making [12], criticism of NICE guideline rec-
ommendations remain. For instance, the recent NICE
guideline on psychosis and schizophrenia [41] has been
criticised because its recommendations on cognitive
behaviour therapy for schizophrenia became more dir-
ective despite no updated review of research evidence
since 2009 [42]. An issue of central importance is
therefore more frequent review by NICE of its evidence
base for its recommendations, perhaps by an ongoing
meta-analysis and a standing committee to review NICE
clinical guidelines if there is sufficient evidence to poten-
tially overturn recommendations and issue an update to
the guideline. Furthermore, NICE clinical guidelines may
be seen as over-reliant on the results of randomised con-
trolled trials that often exclude most of the patients that
the guideline would be applied to and extrapolate average
Box 3. Potential harms of mandatory implementation
of NICE Clinical Guidelines in bipolar disorder
1. Poor recommendations because scientific evidence is lacking,
misleading or misinterpreted [38].
2. Recommendations influenced by personal opinion of key
members of clinical guideline, professional interest, financial
or professional conflict of interest [12, 57].
3. Lack of consistency in recommendations between national
clinical guidelines for the same conditions [39].
4. Institutionalise delivery of ineffective, harmful, or wasteful
interventions [38].
5. Professionals and NHS organisations unfairly judged by
quality standards or other measures that are not in their
control [38].
6. Uncertainty over cost and impact of NICE clinical guidelines
if there are unanticipated effects; costs may sometimes
increase if, for instance, more patients are referred to
secondary care without any improvement in outcome [38].
7. Perceived threat to independence of health professionals and
their ability to personalise care of people with atypical
presentations [38, 50].
8. Perceived threat to patient-centred care because clinical
guidelines are thought to predetermine clinical decision-making
without consideration of patient preference [38].
9. Professional disagreement over the nature of evidence
underlying clinical decision-making [57, 65].
10.NICE guidelines discount learning from clinical practice and
non-random controlled trial evidence on interventions that
nevertheless may be informative for practice [66, 67].
11.Increased demand for training, time and other resources
among health professionals on how to use and what to
deliver in NICE clinical guidelines [68, 69].
12.Lack of consideration of comorbidity, atypical presentation,
and clinical uncertainty since clinical guidelines cannot
predict every clinical situation [38].
13.Discourage individual innovation that is inconsistent with
NICE clinical guideline care except in research [70].
14.Complexity of information in NICE clinical guidelines seen
as a potential barrier to obtaining care by some patients who
lack confidence or trust in dealing with NHS professionals or
organisations [71].
15.Relative absence of research to understand why some
clinicians seem to ignore clinical guidelines so a mandatory
requirement for implementation may not be effective
[50, 72].
16.Mandatory implementation of guidelines may open NHS
bodies to additional legal challenges and complaints if NICE
clinical guidelines are not followed by them.
Note. Sources for each statement given by reference.
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group effects to individuals. Some critics would argue that
randomised controlled trials should not be accepted as
evidence unless they are complemented by evidence from
routine clinical practice such as multi-centre observational
cohort studies [43].
While there is evidence particularly in mental health
that NICE guideline care improves recovery and service
user experience [44–46], such care may not be sufficient
to improve clinical outcomes [47]. Over-adherence to
NICE guidelines can be associated with a lack of patient-
centred care, poor clinical outcomes, and poor service
user experience unless clinicians use their judgement
and listen to patient preferences when they apply NICE
guideline care [48, 49]. For these reasons, NICE clinical
guidelines tend to outline factors for the clinician to
consider and are not and should not be prescriptive,
allowing care to be tailored to individual patient needs
and preferences [12].
While NICE clinical guidelines might reduce variability
in care, they may raise expectations of health profes-
sionals beyond their ability to deliver care given financial
and other constraints, inform articulate rather than dis-
advantaged patients on how to obtain the care they want
thus increasing health inequalities, and restrict health
professionals from personalising care when necessary
[50], particularly in the face of other mental and physical
comorbidities [51]. NICE clinical guidelines contain a
mixture of aspirational or developmental and mature
recommendations; these may need clearer justification
and separation in the NICE clinical guidelines between
aspirational or development, and mature recommenda-
tions, plus investment and a timetable for implementa-
tion from NHS England for key recommendations that
require investment. Mandatory implementation of NICE
guidelines might be seen to discourage the development
and uptake of new technologies in the NHS. However,
the issue is complex [52]. Some technology would enable
NICE clinical guideline care to be delivered more widely,
e.g. mobile phone apps enabling self-completion of stan-
dardised measures of severity of depression [53]. The
biggest problem for technology companies in working
with the NHS is the complexity and unpredictability of
decision-making on commissioning and utilisation of
technology within it [54]. National clinical guidelines and
processes may provide clarity and greater certainty, im-
proving market conditions for the development, uptake,
and sustainability of technology and other innovation
within the NHS [54].
Barriers and drivers to implementation of NICE guidelines
for bipolar disorder
Table 1 summarises barriers and drivers to the imple-
mentation of NICE clinical guidelines for bipolar dis-
order. The Health and Social Care Act (2012) required
all NHS organisations to consider NICE clinical guide-
lines in all commissioning and service delivery, but there
has been a collective lack of leadership by political, pro-
fessional, managerial, or patient advocates so they re-
main largely unimplemented. There may still be doubt
over the wisdom of enforcing NICE clinical guideline
care because of the fear of unintended consequences.
Some NICE clinical guidelines encounter professional
resistance, particularly over some recommendations. For
instance, NICE Clinical Guideline 58 on prostate cancer
made five recommendations that were met with wide-
spread professional disagreement according to a national
survey in 2008 although 60 % agreed the guideline as a
whole would improve patient care. Two years later, two
of these five recommendations received widespread sup-
port, two had the same level of professional disagreement,
and one had even less support [55]. Some members of
professions do not value evidence-based medicine, relying
on other sources of evidence, such as peer group experi-
ence, to drive their decision making [56]. However, on the
whole, NICE clinical guideline care is more likely to obtain
professional support than other policy at a national and
local level [22].
The legitimacy of a clinical guideline and mistrust of it
can arise when an organisation developing the guideline
or key members of the committee or panel devising the
guideline have conflicts of interest raising concerns
about bias in favour of the interests [57]. In the United
States, a survey found that 71 % of chairs of clinical
policy committees had financial conflicts of interest
while 84 % of doctors have expressed concern about in-
dustry influence over clinical guidelines [58]. NICE it-
self is publicly funded as a non-departmental public
body of the Department of Health in the United King-
dom. NICE requires all conflicts of interest of members
of clinical guideline committees to be reported before
appointment and at each meeting; any member removes
themselves from any decision that might be compromised
by a conflict of interest. However, there are also concerns
about other potential conflicts of interest such as the pro-
motion of professional disciplinary issues and individual
or groups of individuals’ professional interests on NICE
clinical guideline development groups. Recently, NICE has
started to appoint chairs of committees who are not ex-
perts in the condition under review; however, there is a
danger that the richness of discussions at clinical guideline
meetings is diluted with the production of an inferior
guideline if all professionals with a conflict of interest are
excluded from clinical guideline committees [59].
Responsibility for the implementation of NICE clinical
guidelines is shared according to the Health and Social
Care Act (2012) across a complex network involving
over 620 different professional, healthcare, and social
care organisations in the NHS (Fig. 1), each of whom
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may unilaterally decide which recommendations they
choose to implement or not. Given that the care path-
way runs across multiple organisations in one locality
and there are multiple independently functioning local-
ities, such an approach inevitably results in more vari-
ation in care and inefficient and ineffective care
compared with the care outlined in the guideline unless
the implementation of NICE clinical guidelines was
mandatory. Nationally, there are no clear strategies for
their implementation and no organisation is responsible
for their implementation, jointly or separately. Policy in
mental health is also extremely complex and might
contradict itself, e.g. the draft Bipolar Disorder Quality
Standards 2015, document refers to 18 other policy
documents for the reader to consider at the same time
[10]. NICE itself confines its implementation efforts to
its own website and a minimal workforce who work re-
gionally on implementation of all their guidelines. NICE
has developed many resources that may help the imple-
mentation of guidelines, such as guides for commis-
sioners, and have also considerably improved the internal
consistency of the guidelines so that they are increasingly
compatible with each other and with other NHS policies.
Research on the implementation of any innovation pro-
vides few consistencies. A meta-analysis of randomised
controlled trials of tailored approaches to the implementa-
tion of single interventions taking into consideration the
local context of care by involving local practitioners and
Table 1 Barriers to mandatory implementation of NICE clinical guidelines for bipolar disorder and their mitigation
Type of barrier Nature of barrier Mitigation against barrier
Policy a) Lack of political, managerial, and professional
leadership in mandating their implementation
versus contest and ignorance of clinical guidelines
Affirmation of importance of implementation of
NICE clinical guidelines unless there is a compelling
reason not to by leaders
b) Complexity of policy directed towards health
and social care including mental health
Consider rationalisation of policy; obligation by NHS
England, NICE, and professional bodies to ensure




a) Multitude of NHS professional and social care
bodies with overlapping roles, responsibilities,
and differing or unclear lines of accountability
Consider rationalisation of organisation of care; require
all agencies to focus on implementation of NICE
guidelines with other agencies to improve effectiveness
and efficiency of clinical pathways in line with NICE
clinical guidelines
b) Concern over professional and personal
conflict of interest in development of NICE
clinical guidelines, lack of psychiatric involvement
because of pharmaceutical industry conflict of
interest, and insufficient professional and NHS
organisational engagement
Improve processes of developing clinical guidelines in
line with Institute of Medicine’s recommendations to
obtain full multidisciplinary professional, service user,
and NHS input into NICE clinical guidelines, and manage
any conflict of interest
Education NICE clinical guidelines are low priority for training,
licensing, continuing professional development,
appraisal, and revalidation by professional and NHS
workforce organisations
Affirm that principles, e.g. recovery and content of NICE
clinical guideline care, are of central importance and
design systems to ensure they are mandatory for training,
examination, licensing, appraisal, continuing professional
development, and revalidation
Economic a) Some high cost items recommended in NICE
clinical guidelines or innovation, e.g. technology;
service redesign to improve care requiring investment
with later cost offset
NHS England with other bodies, e.g. Academic Health
Science Networks (AHSN), work with NICE to set timetable
for implementation with non-recurrent funding for set
up costs
b) Guideline may discourage innovation and research
by setting out specific recommendations for care
Guideline highlights areas of uncertainty for innovation
and research
c) Overall uncertainty about costs, benefits,
unintended consequences, and harms with
mandatory implementation of NICE clinical
guidelines
Overall research and monitoring study commissioned
with review dates to consider results and mitigating
action
Treatment Professionals will over rigidly apply or not conform
to NICE clinical guidelines
Monitoring of NICE quality standards and service user
experience as routine requirement of commissioning,
inspection of providers, professional appraisal,
and revalidation
Service user Lack of knowledge of public about NICE guidance Requirement of all NHS providers and AHSN to work
with NICE to disseminate patient versions of NICE
clinical guidelines and how
to use them
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service users, showed evidence of benefits to patients [60].
A locally-tailored approach systematically identifying and
addressing barriers and drivers to the implementation of
NICE clinical guidelines has shown promise [61]. How-
ever, the evidence on the cost effectiveness of these imple-
mentation approaches towards NICE clinical guidelines
across a whole clinical pathway is lacking. One approach
to achieving such implementation at a local level has been
involving networks of professionals and service users
working together under umbrella organisations such as
the National Institute of Health Research Collaborations
for Leadership in Health Research and Care, Academic
Health Science Networks, and strategic clinical networks.
Implementing evidence-based care in the local context so
that it is effective and efficient through these networks
can be experienced as an enjoyable challenging and pro-
ductive experience [62, 63]. Such approaches require
training and support, for instance, through knowledge
brokers with implementation and quality assurance ex-
pertise working alongside teams of clinicians, service
users, commissioners, and managers [64].
Summary
The mandatory implementation of NICE clinical guide-
lines as the minimum standard of care offers the prospect
of delivering high quality care at reduced cost while pro-
moting equity of access and respect for patient and carers’
views and choices, provided the guideline is seen as the
starting basis for good clinical care rather than constrain-
ing patient-centred care and are kept up to date and trust-
worthy. Although such an approach is logical based on
how the clinical guidelines are derived, there is a limited
amount of evidence of economic benefit of the implemen-
tation of evidence-based guidelines for bipolar disorder.
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